Suven Life Sciences

Suven, Cohance aim to double combined biz revenue to Rs 6,000 cr by FY29

Merger-bound Suven Pharmaceuticals and Cohance Lifesciences aim to more than double their combined revenue to around Rs 6,000 crore by FY29 by undertaking both organic and inorganic growth routes, a top company official said. The entities reported a combined revenue of Rs 2,392 crore in FY24. The merged entity aims to put in place an aggressive plan to more than double revenue to Rs 6,000 crore by FY29 through both organic and inorganic growth routes, Suven Pharma Managing Director Prasada Raju said. The merger between Suven and Cohance has received approval from both NSE & BSE. As directed by National Company Law Tribunal (NCLT), the shareholders meeting of both Suven Pharmaceuticals and Cohance Lifesciences amalgamation will be held on November 28, 2024. Once finalised and approved, the combined entity will focus on three core growth drivers: pharma CDMO, specialty chemicals CDMO, and active pharmaceutical ingredients (APIs). "Together, we're building a powerhouse poised to ...

Suven Life hits life high after positive result for its depression drug

The study aimed to evaluate the safety and tolerability of Ropanicant in patients with Major Depressive Disorder

Pharma shares rally; Suven, Granules, Ajanta, Jubilant surge over 5%

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Stock exchanges approve Cohance-Suven Pharma merger; NCLT application filed

The newly formed company is said to focus on three main verticals - Pharma CDMO, Agrochemicals CDMO, and API manufacturing

Pharma shares shine; Dr Reddy's, FDC, Glenmark, Suven trade at record highs

Shares of Wockhardt hit a multi-year high of Rs 943.20, zooming 65 per cent in past nine trading days.

Suven Pharma stock can surge up to 19% from here; check key levels

Technical charts suggest that Suven Pharma may trade with a positive bias in the near-term, provided the stock manages to hold above these key support levels.

Will pharma stocks continue their dream rally in FY25?

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

CCI clears Berhyanda's 76% stake acquisition in Suven Pharmaceuticals

The Competition Commission of India (CCI) on Thursday said it has cleared Berhyanda Ltd's acquisition of a 76.10 per cent stake in pharmaceutical firm Suven Pharmaceuticals Ltd. Berhyanda Ltd is a wholly-owned subsidiary of Berhyanda Midco Ltd, which is an affiliate of Advent International Corporation. The proposed combination relates to the acquisition by Berhyanda Ltd for up to 76.10 per cent of the voting share capital of Suven Pharmaceuticals Ltd, by way of a share purchase agreement dated December 26, 2022, and pursuant to the mandatory open offer in compliance with Sebi's SAST (Substantial Acquisition of Shares and Takeovers) regulations, according to an official release. Suven Pharmaceuticals Ltd is a biopharmaceutical company that offers its services to global pharmaceutical and agrochemical majors. Deals beyond a certain threshold require approval from the regulator, which keeps a tab on unfair business practices in the marketplace.

We aim to be one of India's top CDMO, API players: Advent's Shweta Jalan

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

Sensex, Nifty recoup losses, end flat; auto stocks dip, PB Fintech gains 8%

CLOSING BELL: The S&P BSE Sensex ended with a marginal loss of 88 points, while the Nifty held the 18,300-level on Friday.

Stocks to watch: RIL, Tata Motors, Nykaa, ABFRL, Equitas SFB, Suven Life

Stocks to watch today: Tata Motors bagged order for 1,000 buses from Haryana Roadways; ABFRL inked pact with Galeries Lafayette to open luxury department stores in India

Suven starts Phase 3 trial for first home-grown Alzheimer's drug

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

Suven Life freezes at 20% upper circuit as board to mull rights issue

The stock had hit a 52-week low of Rs 62 on June 20, 2022, and has corrected 50 per cent from its record high level of Rs 124 touched on October 8, 2021

Stocks to Watch: Telecom, LIC Hsg Fin, KEC Intl, Suven Life, IIFL Finance

Stocks to Watch Today: Indiabulls Housing Finance and RBL Bank are the two stocks in F&O ban period on Tuesday.

Sebi disposes of proceedings against Suven Life Sciences, others

Markets regulator Sebi on Thursday disposed of proceedings against Suven Life Sciences Ltd, Jasti Family Trust and four other individuals, including the firm's chairman and CEO Venkateshwarlu Jasti

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

Healthcare companies to post decent growth in revenues in Q3FY21

Suven Life Sciences tumbles 20% as SUVN-502 misses target in phase-2 trial

As part of the study, Suven tested the drug as a unique triple combination with Aricept (donepezil) and Namenda (memantine) on 564 patients in the US for at least one year

Suven gets US court's approval to buy assets of Rising Pharmaceuticals

The company has completed a 'stalking horse agreement' as mandated by a bankruptcy court to buy the assets of Rising Pharmaceuticals, Suven Life Sciences said in a regulatory filing

Suven Life Sciences enters asset purchase agreement to buy Rising Pharma

This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company

Suven Life Sciences gets patent for neuro drug in Australia, Singapore

These patents are valid through 2036, the company said in a BSE filing